186 related articles for article (PubMed ID: 30403365)
1. Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis.
Hyun JW; Kim Y; Kim G; Kim SH; Kim HJ
Mult Scler; 2019 Dec; 25(14):1942-1945. PubMed ID: 30403365
[TBL] [Abstract][Full Text] [Related]
2. Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
Baker D; Giovannoni G; Schmierer K
Mult Scler Relat Disord; 2017 Nov; 18():181-183. PubMed ID: 29141806
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab.
Aguirre C; Meca-Lallana V; Sánchez P; Vivancos J
Mult Scler Relat Disord; 2019 Oct; 35():270-271. PubMed ID: 31442904
[TBL] [Abstract][Full Text] [Related]
4. Ocrelizumab for Post-Alemtuzumab Paradoxical Disease Activity in Highly Active Multiple Sclerosis.
Adamec I; Habek M
Clin Neuropharmacol; 2022 Sep-Oct 01; 45(5):139-141. PubMed ID: 36093911
[TBL] [Abstract][Full Text] [Related]
5. [Change of therapeutic algorithm in sclerosis multiplex based on two case reports].
Biernacki T; Bencsik K; Kincses ZT; Sandi D; Fricska-Nagy Z; Faragó P; Vécsei L
Ideggyogy Sz; 2017 Nov; 70(11-12):381-387. PubMed ID: 29870646
[TBL] [Abstract][Full Text] [Related]
6. Multiple sclerosis: structural and functional integrity of the visual system following alemtuzumab therapy.
Wang C; Barton J; Kyle K; Ly L; Barnett Y; Hartung HP; Reddel SW; Beadnall H; Taha M; Klistorner A; Barnett MH
J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1319-1324. PubMed ID: 34187865
[TBL] [Abstract][Full Text] [Related]
7. Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab.
Guevara C; Villa E; Cifuentes M; Naves R; Grazia J
Mult Scler Relat Disord; 2020 Sep; 44():102314. PubMed ID: 32593959
[No Abstract] [Full Text] [Related]
8. [Alemtuzumab therapy 2017].
Biernacki T; Bencsik K; Sandi D; Vécsei L
Ideggyogy Sz; 2017 Nov; 70(11-12):371-380. PubMed ID: 29870645
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune encephalitis following alemtuzumab treatment of multiple sclerosis.
Giarola B; Massey J; Barnett Y; Rodrigues M; Sutton I
Mult Scler Relat Disord; 2019 Feb; 28():31-33. PubMed ID: 30553166
[TBL] [Abstract][Full Text] [Related]
10. Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab.
Hümmert MW; Deppe J; Pul R; Wurster U; Schwenkenbecher P; Sühs KW; Bronzlik P; Stangel M; Skripuletz T
Mult Scler Relat Disord; 2018 May; 22():87-89. PubMed ID: 29631243
[TBL] [Abstract][Full Text] [Related]
11. Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis.
Wehrum T; Beume LA; Stich O; Mader I; Mäurer M; Czaplinski A; Weiller C; Rauer S
Neurology; 2018 Feb; 90(7):e601-e605. PubMed ID: 29352101
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVID.
Fiorella C; Lorna G
Mult Scler Relat Disord; 2020 Nov; 46():102447. PubMed ID: 32835901
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following Natalizumab break: Clinical case and literature review.
Federle L; Puthenparampil M; Stenta G; Paolo G; Francesco P
Mult Scler Relat Disord; 2019 May; 30():262-264. PubMed ID: 30851640
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment.
Haas J; Würthwein C; Korporal-Kuhnke M; Viehoever A; Jarius S; Ruck T; Pfeuffer S; Meuth SG; Wildemann B
Front Immunol; 2019; 10():1204. PubMed ID: 31214176
[TBL] [Abstract][Full Text] [Related]
15. Effector and regulatory B cells in Multiple Sclerosis.
Staun-Ram E; Miller A
Clin Immunol; 2017 Nov; 184():11-25. PubMed ID: 28461106
[TBL] [Abstract][Full Text] [Related]
16. Sarcoidosis following alemtuzumab treatment for multiple sclerosis.
Willis MD; Hope-Gill B; Flood-Page P; Joseph F; Needham E; Jones J; Coles A; Robertson NP
Mult Scler; 2018 Nov; 24(13):1779-1782. PubMed ID: 30307364
[TBL] [Abstract][Full Text] [Related]
17. The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis.
Rolla S; Maglione A; De Mercanti SF; Clerico M
Cells; 2020 Jun; 9(6):. PubMed ID: 32503344
[TBL] [Abstract][Full Text] [Related]
18. Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment.
Barone S; Scannapieco S; Torti C; Filippelli E; Pisani V; Granata A; Console D; Demonte G; Tallarico T; Polidoro S; Quattrone A; Valentino P
Mult Scler Relat Disord; 2018 Feb; 20():6-8. PubMed ID: 29272733
[TBL] [Abstract][Full Text] [Related]
19. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
[TBL] [Abstract][Full Text] [Related]
20. A case of acute fulminant multiple sclerosis treated with alemtuzumab.
Gobbin F; Marangi A; Orlandi R; Richelli S; Turatti M; Calabrese M; Forgione A; Alessandrini F; Benedetti MD; Monaco S; Gajofatto A
Mult Scler Relat Disord; 2017 Oct; 17():9-11. PubMed ID: 29055482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
